# C_2016207EN.01001501.xml

| 10.6.2016 | EN | Official Journal of the European Union | C 207/15 |
| --- | --- | --- | --- |

10.6.2016

EN

Official Journal of the European Union

C 207/15

---

Prior notification of a concentration

(Case M.7975 — Mylan/Meda)

(Text with EEA relevance)

(2016/C 207/07)

| 1. | On 1 June 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Mylan NV (the Netherlands, ‘Mylan’) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Meda AB (Sweden, ‘Meda’) by way of public bid announcement. |
| --- | --- |

1.

On 1 June 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Mylan NV (the Netherlands, ‘Mylan’) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Meda AB (Sweden, ‘Meda’) by way of public bid announcement.

1

| 2. | The business activities of the undertakings concerned are:






  — | Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

| — | Meda is an international speciality company that manufactures and distributes pharmaceuticals. |
| --- | --- |

—

Meda is an international speciality company that manufactures and distributes pharmaceuticals.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7975 — Mylan/Meda, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7975 — Mylan/Meda, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---